Justification

2. Key points of the resolution .................................................................................... 2 2.1 Additional benefit of the medicinal product in relation to the appropriate comparator therapy ................................................................................................................... 3 2.1.1 Approved therapeutic indication of Empagliflozin (Jardiance) in accordance with the product information ......................................................................................... 3 2.1.2 Appropriate comparator therapy ..................................................................... 3 2.1.3 Extent and probability of the additional benefit .............................................. 6 2.1.4 Summary of the assessment .......................................................................... 13 2.2 Number of patients or demarcation of patient groups eligible for treatment ......... 14 2.3 Requirements for a quality-assured application ..................................................... 14 2.4 Treatment costs .................................................................................................... 14